Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PPARG | P37231 | 6/20 | 0.48 |
| ▸ | PTGES | O14684 | 5/20 | 0.48 |
| ▸ | ALOX5 | P09917 | 5/20 | 0.48 |
| ▸ | FFAR1 | O14842 | 2/20 | 0.47 |
| ▸ | MEN1 | O00255 | 1/20 | 0.46 |
| ▸ | NPC1 | O15118 | 1/20 | 0.46 |
| ▸ | RAB9A | P51151 | 1/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.46 |
| ▸ | MMP2 | P08253 | 1/20 | 0.45 |
| ▸ | MMP3 | P08254 | 1/20 | 0.45 |
| ▸ | S1PR1 | P21453 | 4/20 | 0.45 |
| ▸ | S1PR3 | Q99500 | 2/20 | 0.45 |
| ▸ | S1PR5 | Q9H228 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1856529 | 0.90 | LTA4H (0.50) | ALOX5FFAR1MMP2MMP3 | |
| SCHEMBL1863760 | 0.88 | GRIK1 (0.47) | PPARGPTGESALOX5MMP2MMP3 | |
| SCHEMBL8041180 | 0.85 | PPARG (0.61) | PPARGPTGESALOX5FFAR1MEN1 | |
| SCHEMBL1855513 | 0.77 | ALDH1A1 (0.47) | — | |
| SCHEMBL1865673 | 0.75 | LTA4H (0.55) | ALOX5FFAR1NPC1RAB9AMMP2 | |
| SCHEMBL11269284 | 0.75 | SMN1; SMN2 (0.51) | PPARGPTGESALOX5MEN1NPC1 | |
| SCHEMBL27400118 | 0.75 | PTGES (0.46) | PPARGPTGESALOX5MMP2MMP3 | |
| SCHEMBL1857414 | 0.74 | SMN1; SMN2 (0.48) | PPARGALOX5MEN1NPC1KMT2A | |
| SCHEMBL1857400 | 0.74 | POLB (0.49) | MMP2MMP3 | |
| SCHEMBL1858392 | 0.73 | ALDH1A1 (0.57) | ALOX5MEN1NPC1RAB9AKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110105544-A1 | CARBOXYLIC DERIVATIVES FOR USE IN THE TREATMENT OF CANCER | CRYSTAX PHARMACEUTICALS, S.L. (ES) | 2011-05-05 | — | — | US | disclosed |
| WO-2009080722-A2 | CARBOXYLIC DERIVATIVES FOR USE IN THE TREATMENT OF CANCER | CRYSTAX PHARMACEUTICALS, S.L. (ES) | 2009-07-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110105544-A1 | CARBOXYLIC DERIVATIVES FOR USE IN THE TREATMENT OF CANCER | AKR1C3, TPD52L2, HCCS | PPARG 3250/4885PTGES 3899/4885ALOX5 1605/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.